Award details

Analysis of transgenic mouse lines expressing the NPM-ALK oncogenic tyrosine kinase

Reference	BBS/E/B/0000H076
Principal Investigator / Supervisor	Dr Denis Alexander
Co-Investigators / Co-Supervisors
Institution	Babraham Institute
Department	Babraham Institute Department
Funding type	Research
Value (£)	80,503
Status	Completed
Type	Institute Project
Start date	01/01/2003
End date	30/06/2005
Duration	30 months

Abstract

ALKoma is a type of non-Hodgkin's lymphoma affecting mainly children and young adults. Patients that suffer from this form of cancer carry a malfunctional gene called NPM-ALK. Although of a relatively good prognosis, the combination chemotherapy treatment currently employed is in itself an ordeal for patients, particularly those of a young age. Our research aims are to develop mouse models of the disease in order that these can be used to investigate the cell machinery used to allow the cancer to develop. Once the signalling pathways have been elucidated it will be possible to determine the best treatment for the disease. For example in recent years kinase inhibitor 'drugs' have been developed for the treatment of a form of leukaemia that expresses a kinase similar to NPM-ALK called Bcr-Abl. These drugs target the malfunctional protein and therefore do not have the debilitating side effects of common chemotherapy drugs and may be suitable for ALKoma treatment.

Summary

unavailable

Committee	Closed Committee - Biochemistry & Cell Biology (BCB)
Research Topics	X – not assigned to a current Research Topic
Research Priority	X – Research Priority information not available
Research Initiative	X - not in an Initiative
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search